• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gh Research Plc (NQ: GHRS )

    11.58 -0.38 (-3.18%)
    Streaming Delayed Price Updated: 11:55 AM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,251
    Open 12.13
    Bid (Size) 11.38 (1)
    Ask (Size) 11.74 (2)
    Prev. Close 11.96
    Today's Range 11.58 - 12.36
    52wk Range 5.050 - 14.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
    Via Talk Markets
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga

    Performance

    YTD
    +116.45%
    +116.45%
    1 Month
    -12.80%
    -12.80%
    3 Month
    +5.27%
    +5.27%
    6 Month
    +117.67%
    +117.67%
    1 Year
    -7.66%
    -7.66%

    More News

    Read More
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    Via Talk Markets
    GH Research: Q4 Earnings Insights
    Via Benzinga
    GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
    Via InvestorPlace
    GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    Via Talk Markets
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
    Via Talk Markets
    March Recap: Largest Psychedelic Drug Stocks Up Another 5%
    Via Talk Markets
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
    Via Talk Markets
    Exposures Product Safety
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
    Via Talk Markets
    GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
    Via Benzinga
    GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
    Via Talk Markets
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
    Via Benzinga
    5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
    Via Talk Markets
    Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Via Benzinga
    Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
    Via Benzinga
    GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
    From GH Research PLC
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.